Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy.
Zhou Q, Tu X, Hou X, Yu J, Zhao F, Huang J, Kloeber J, Olson A, Gao M, Luo K, Zhu S, Wu Z, Zhang Y, Sun C, Zeng X, Schoolmeester KJ, Weroha JS, Hu X, Jiang Y, Wang L, Mutter RW, Lou Z.
Zhou Q, et al. Among authors: zhu s.
Drug Resist Updat. 2024 Apr 16;74:101085. doi: 10.1016/j.drup.2024.101085. Online ahead of print.
Drug Resist Updat. 2024.
PMID: 38636338